Implications for body weight extremes in solid organ transplantation
© 2021 Pharmacotherapy Publications, Inc..
The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life-sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non-pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug-drug interactions with popular weight management products.
| Errataetall: |
CommentIn: Pharmacotherapy. 2021 Jan;41(1):4-5. - PMID 33598986 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 41(2021), 1 vom: 10. Jan., Seite 44-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Campara, Maya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BMI |
|---|
| Anmerkungen: |
Date Completed 27.09.2021 Date Revised 28.09.2021 published: Print-Electronic CommentIn: Pharmacotherapy. 2021 Jan;41(1):4-5. - PMID 33598986 Citation Status MEDLINE |
|---|
| doi: |
10.1002/phar.2493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318670216 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318670216 | ||
| 003 | DE-627 | ||
| 005 | 20231225165833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/phar.2493 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318670216 | ||
| 035 | |a (NLM)33301647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Campara, Maya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implications for body weight extremes in solid organ transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2021 | ||
| 500 | |a Date Revised 28.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Pharmacotherapy. 2021 Jan;41(1):4-5. - PMID 33598986 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Pharmacotherapy Publications, Inc. | ||
| 520 | |a The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life-sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non-pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug-drug interactions with popular weight management products | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BMI | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a transplant | |
| 650 | 4 | |a underweight | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Lourenco, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Melaragno, Jennifer I |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Tiffany E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 41(2021), 1 vom: 10. Jan., Seite 44-58 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:1 |g day:10 |g month:01 |g pages:44-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2493 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 1 |b 10 |c 01 |h 44-58 | ||